Biotech IV Monitor

ATAI — AtaiBeckley Inc.

$2.6B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for AtaiBeckley Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$2.6B

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2 VLS-01
Treatment Resistant Depression
August 1, 2026
Ongoing
Phase 3 BPL-003
Resistant Depression
November 2026
Trial Planned

Companies working on similar indications

Discussion

No messages yet. If you follow ATAI, you can start the conversation.
Track ATAI in real time
See live implied volatility for ATAI and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ATAI
Contact — questions or corrections about ATAI: dukeupt@gmail.com